

Amendments to the Claims:

Following is a complete listing of the claims pending in the application, as amended:

1. (Currently amended) A δ V1-1 peptide comprising an amino acid sequence that has ~~at least 50%~~ greater than 80% identity with SEQ ID NO:4 and activity as an antagonist of δ PKC.

2. (Currently Amended) The peptide of claim 1 selected from ~~SEQ ID NOS:34-48~~ the group consisting of SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, and SEQ ID NO:41.

Claims 3-6 (Canceled)

7. (Original) The peptide according to claim 1, wherein said peptide is recombinantly produced.

8. (Original) The peptide of claim 1, wherein the peptide is chemically synthesized.

9. (Original) The peptide of claim 1, wherein the peptide is encoded by a polynucleotide.

Claims 10-60 (Canceled)

61. (Previously presented) The peptide of claim 1 having a terminal cysteine.

62. (Previously presented) The peptide of claim 2 having a terminal cysteine.

63-65. (Canceled)

66. (Currently amended) A δ V1-1 peptide consisting essentially of an amino acid sequence that has greater than 80% identity with SEQ ID NO:4 and having activity as an antagonist of δ PKC.

67. (Previously presented) The peptide of claim 66 having a terminal cysteine.

68-69. (Canceled)

70. (Previously presented) A peptide consisting of SEQ ID NO:4.

71. (New) The peptide of claim 70 having a terminal cysteine.